Pharma Deal Landscape
A live view across all deal types.
A live, decision-grade view of the pharma deal landscape — M&A, licensing, partnerships and financings — segmented by TA, modality and stage.
"What does the deal landscape tell us about where to compete and where to bid?"
Deal landscape blends M&A, licensing, partnerships and financings into one view that reveals capital flow, valuation curves and strategic intent across pharma.
Pharma deal landscape works only as a unified view across M&A, licensing, partnerships and financings. Single-feed tracking misses 60% of meaningful signal.
What we’re seeing in the data.
Cross-deal intelligence beats single-type tracking
M&A + licensing + partnerships together reveal moves that any single feed misses.
Valuation curves shift quarterly
Hot TA premiums change quarter-to-quarter.
Strategic intent visible in pattern
Cluster of deals reveals acquirer thesis.
How to think about it.
-
01
Aggregate all deal types
M&A + licensing + partnerships + financings.
-
02
Tag by TA, modality, stage
Cross-axis slicing.
-
03
Track valuation curves
Multiples by TA and stage.
-
04
Surface strategic patterns
Acquirer / licensee clusters.
What separates a good answer from a defensible one.
Many terms not disclosed.
US/EU more visible than Asia.
Financings precede deal announcements.
Where the signal comes from.
Common questions.
Why aggregate types?
Patterns invisible in single-type feeds.
Refresh cadence?
Live for events, weekly for synthesis.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist